AHA 2024 - Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin – an investigational oral Lp(a) inhibitor – was investigated in patients with elevated Lp(a) levels and high CV risk.
advertisement
Promising results with oral Lp(a) inhibitor in phase 2 trial
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in JAMA
Release date: 19 November 2024
Recommended
Details
Presenters
Overview
AHA 2024 - Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin – an investigational oral Lp(a) inhibitor – was investigated in patients with elevated Lp(a) levels and high CV risk.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in JAMA
Release date: 19 November 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
0.25 credits
<p>IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis</p>
CME/CE
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
1.00 credits
<p>Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies</p>
MinuteCE®
Chemotherapy Strategies for Metastatic PDAC
0.25 credits
<p>Chemotherapy Strategies for Metastatic PDAC</p>
MinuteCE®
Partnering with Patients: Building Effective Communication and Support in HF Care
0.75 credits
<p>Partnering with Patients: Building Effective Communication and Support in HF Care</p>
MinuteCE®
A Practical Guide to Prescribing in HF
0.75 credits
<p>A Practical Guide to Prescribing in HF</p>
MinuteCE®
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
1.25 credits
<p>Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?